E2F transcription factors and digestive system malignancies: how much do we know?

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• The E2F family of transcription factors plays a crucial role in regulating cell cycle progression and apoptosis.
• While traditionally classified as activators or repressors, their in vivo roles in human cancers are complex and context-dependent.
• Understanding E2F family member expression in digestive system malignancies is vital for predicting patient outcomes and guiding treatment strategies.

Purpose of the Study:

• To review the current knowledge on E2F family member expression in digestive system cancers.
• To elucidate the clinical implications of E2F expression for patient prognosis and treatment.
• To explore potential therapeutic strategies targeting E2F in cancer.

Main Methods:

• Literature review of studies on E2F expression in digestive system malignancies.
• Analysis of clinical data correlating E2F expression with tumor grade, patient survival, and treatment response.
• Examination of experimental studies on E2F-based gene therapy.

Main Results:

• E2F1 acts as a tumor suppressor in esophageal, gastric, colorectal adenocarcinomas, and hepatocellular carcinoma (HCC), correlating with better survival.
• E2F1 may act as a tumor promoter in pancreatic ductal adenocarcinoma and esophageal squamous cell carcinoma, linked to poorer survival.
• E2F4 promotes carcinogenesis in colorectal, gastric, and hepatic cancers; E2F8 is upregulated in HCC.

Conclusions:

• E2F family members exhibit tissue-specific roles in digestive system carcinogenesis, impacting prognosis differently across cancer types.
• Targeted therapies using E2F modulators require consideration of these tissue-dependent functions.
• Further in vivo research is needed to fully understand E2F roles in cancer development and progression.